Search Results
Oct 28, 2025, 08:00 ET Ultima Accelerates Adoption in Asia with Key Leadership Appointment
companies including Thermo-Fisher Scientific, Life Technologies, Applied Biosystems, Macrogen, and Spectral Genomics. Jason holds a PhD from Thomas Jefferson University and a BS from Carnegie Mellon University. "We are pleased to attract strong leaders like Jason
More news about: Ultima Genomics
Oct 28, 2025, 07:35 ET Myrio Therapeutics Announces Collaboration with Leading Research Institutions to Advance Solid Tumor T cell Immunotherapeutics
development of next-generation T cell immunotherapies Partnership with T cell experts Daniel J Powell Jr., PhD, and Mark Yarmarkovich, PhD PHILADELPHIA, NEW YORK and MELBOURNE, Australia, Oct. 28, 2025
More news about: Myrio Therapeutics
Oct 28, 2025, 07:30 ET Syantra, Inc. Expands Reach and Impact to New Zealand through New Partnership with Breast Cancer Foundation NZ
working with us and our people to innovate equitable solutions.", says Breast Cancer Foundation NZ Innovation Development Manager, Hannah Holtkamp, PhD. "It is exciting to see Syantra push forward on creating new accessible screening options for women around the world like Onco-ID, and have this partnership
More news about: Syantra Inc.
Oct 28, 2025, 07:00 ET In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer
[email protected] Investor Relations Contact: Aman Patel, CFA & Adanna G. Alexander, PhD ICR Healthcare [email protected]
More news about: Cytosorbents Corp
Oct 28, 2025, 06:45 ET Hycroft Files Third Quarter 2025 10-Q and Provides Corporate Update
progress we've made—and are even more excited about the road ahead. Diane R. Garrett, PhD, President and CEO Third Quarter 2025 Highlights
More news about: Hycroft Mining Holding Corporation
Oct 28, 2025, 06:07 ET Distinct Brain Features in Football Players May Tell Who Is at Risk of Long-Term Traumatic Disease
Carina Heller, PhD, Brian Im, MD, Shae Datta, MD, and Laura Balcer, MD. Other study co-investigators are Katherine Breedlove, Nicholas Kim, Alana Wickham, Daniel Daneshvar, MD, PhD, Tim Weigand, Tashrif Billah, Ofer Pasternak, PhD, Michael Coleman, Alexander Lin, PhD, and Martha Shenton, PhD, at Harvard
More news about: NYU Langone Health System
Oct 28, 2025, 05:05 ET LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
completely novel drug design in stroke treatment—combining thrombolytic and neuroprotective properties into a single agent," said Thomas Devlin, MD, PhD, Professor of Neurology at the University of Tennessee Health Science Center and Principal Investigator of the study. "The positive results of this trial
More news about: Lumosa Therapeutics Co., Ltd.
Oct 28, 2025, 04:30 ET Women in Life Science Denmark (WiLD) expands mentoring program to support next generation of female leaders in life sciences
contributing to value creation through professional knowledge sharing and network activities. The Initiator of WiLD is Lene Gerlach, PhD, who is a Venture Partner at Hadean Ventures and the Co-Founder and Chair of WiLD. Lene is backed by a strong volunteer board of directors including
More news about: Women in Life Science Denmark (WiLD)
Oct 28, 2025, 04:20 ET LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
completely novel drug design in stroke treatment—combining thrombolytic and neuroprotective properties into a single agent," said Thomas Devlin, MD, PhD, Professor of Neurology at the University of Tennessee Health Science Center and Principal Investigator of the study. "The positive results of this trial
More news about: Lumosa Therapeutics Co., Ltd.
Oct 28, 2025, 03:36 ET Meet the Top Three: Stars of Science Finalists Race Toward the Title of Top Arab Innovator
Among the finalists is Razan Salem Bahabri, a Saudi completing her PhD in biomedical engineering, whose invention uses wearable gaming systems to support stroke patients in their rehabilitation journey. Her innovation merges
More news about: Stars of Science
Oct 28, 2025, 03:02 ET BioCina Announces Appointment of Dr. Thomas Broudy as Chief Executive Officer
background as well, having held postdoctoral appointments at Rockefeller University and Stanford University studying host/microbial genomics. He earned his PhD at Rockefeller in the Laboratory of Bacterial Pathogenesis and Immunology. BioCina recently announced the merger of its Adelaide-based
More news about: BioCina
Oct 28, 2025, 03:02 ET BioCina Announces Appointment of Dr. Thomas Broudy as Chief Executive Officer
background as well, having held postdoctoral appointments at Rockefeller University and Stanford University studying host/microbial genomics. He earned his PhD at Rockefeller in the Laboratory of Bacterial Pathogenesis and Immunology. BioCina recently announced the merger of its Adelaide-based
More news about: BioCina
Oct 27, 2025, 16:30 ET Vapotherm HVT® 2.0 Earns DoD Authority to Operate Certification, Advancing Secure Respiratory Support for Military and VA Hospitals
Jessica Whittle, MD PhD Chief Medical Officer | VP Clinical Research
More news about: Vapotherm, Inc.
Oct 27, 2025, 14:24 ET Music therapy during surgery reduces anesthetic use and stress responses
adds to the growing empirical evidence that the neural effects of patient-preferred music translate to behavioral benefits," said Wendy L. Magee, PhD, Professor of Music Therapy at Temple University's Boyer College of Music and Dance. "For people with disorders of consciousness following brain injury,
More news about: International Association for Music & Medicine
Oct 27, 2025, 11:15 ET Neurotronic Announces Presentation of First Clinical Outcomes of Multi‑Organ Denervation for Type 2 Diabetes and Hypertension
"We are proud to be at the forefront of the emerging field of multi‑organ denervation in collaboration with world experts," said Lixiao Wang, PhD, CEO of Neurotronic, Inc. "Our goal in advancing this novel therapy is to address a large and growing unmet need in patients with cardiometabolic
More news about: Neurotronic
Oct 27, 2025, 08:30 ET Every Patient Matters: Bespoke Digital Endpoint Strategies for Rare Disease Drug Development, Upcoming Webinar Hosted by Xtalks
Clario, Mark Opler, PhD, Chief Research Officer, eCOA Neuroscience; Scott J. Hunter, PhD, Senior Scientific Expert, Neurodevelopmental and Rare Disease, and Epilepsy; Thomas Fuerst, PhD, Chief Science Officer; and Vic Patel, MD, PhD, Vice President & Chief Medical Officer,
More news about: Xtalks
Oct 27, 2025, 08:30 ET Advancing Cell Therapy Development with Integrated Analytical and Process Strategies, Upcoming Webinar Hosted by Xtalks
Kincell Bio, Patrick Kellish, PhD, Senior Scientist, Analytical Development; and Douglas Mogensen, VP, Commercial Development, for the live webinar on Tuesday, November 11, 2025, at 11am
More news about: Xtalks
Oct 27, 2025, 08:30 ET CENTURY LITHIUM RELOCATING DEMONSTRATION PLANT TO TONOPAH, NEVADA
centurylithium.com. ON BEHALF OF CENTURY LITHIUM CORP. WILLIAM WILLOUGHBY, PhD., PEPresident & Chief Executive Officer NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS
More news about: Century Lithium Corp.
Oct 27, 2025, 08:04 ET 29 Physicians from Virginia Cancer Specialists Named to Washingtonian Magazine's Top Doctors List 2025
Alexander I. Spira, MD, PhD, FACP, FASCO, Oncology/Hematology
More news about: Virginia Cancer Specialists
Oct 27, 2025, 08:00 ET Pancreatic Cancer Clinical Trial Data for Diakonos Oncology's DOC1021 Cell-Based Immunotherapy to be Presented at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Cell-Based Immunotherapy for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma Presenting Author: William Decker, PhD, Baylor College of Medicine, Houston, TX Abstract Number: 540 Session Type: Poster Presentation Session Session
More news about: Diakonos Oncology
Oct 27, 2025, 07:30 ET TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
provides patients and their providers with meaningful choices in how they begin treatment with proven long-term benefits," said Esi Lamousé-Smith, MD, PhD, Vice President, Gastroenterology Disease Area Lead, Immunology, Johnson & Johnson Innovative Medicine. "These results underscore our legacy of delivering
More news about: Johnson & Johnson
Oct 27, 2025, 07:14 ET Xcellerant Ventures and Jetstream Founder John Shufeldt Establish the John Shufeldt School of Medicine and Medical Engineering at Arizona State University
the College of Health Solutions. "The connection between ASU Health and Jetstream reflects a unified vision," said Chris Yoo, PhD, Managing Partner at Xcellerant Ventures. "We're investing in both the people and the ideas that will reshape how medicine is practiced and delivered."
More news about: Xcellerant Ventures
Oct 27, 2025, 07:00 ET China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392)
the potential to broaden the reach of CTLA-4-targeting immunotherapy and to improve outcomes for patients living with sqNSCLC." said Pan Zheng, MD, PhD, Co-founder and Chief Medical Officer of OncoC4. "Gotistobart is a next-gen acid pH-sensitive anti-CTLA4 mAb that conferred an
More news about: OncoC4
Oct 27, 2025, 07:00 ET Urano Energy Expands I-70 Uranium Project Through Strategic Acquisition from enCore Energy Corp.
Person The technical information in this news release has been reviewed and approved by Dr. Douglas Underhill, PhD (Geology), MBA, CPG, a Director of Urano Energy Corp. and a Qualified Person as defined by National Instrument 43-101 Standards of Disclosure for Mineral
More news about: Urano Energy Corp.
Oct 27, 2025, 06:51 ET "Trick or Treat": Helping Children Who Have Speech or Language Disorders Enjoy a Halloween Tradition
involved in this holiday pastime, especially for children with speech or language disorders," explains ASHA 2025 President Bernadette Mayfield-Clarke, PhD, CCC-SLP. "Saying 'trick or treat' doorstep after doorstep, answering questions about costumes or candy preferences, and having
More news about: American Speech-Language-Hearing Association (ASHA)